To the Editor In the article about emergency department (ED)–initiated buprenorphine/naloxone treatment for opioid dependence, Dr D’Onofrio and colleagues1 omitted important information and then focused on the most optimistic outcomes to infer a benefit.
First, drug trials should monitor and report harms of treatment. Yet the authors made no mention of harms. Was there any mortality? Were there any overdoses or adverse drug reactions?
Swartz AW. Opioid Dependence Treatment in the Emergency Department. JAMA. 2015;314(8):834-835. doi:10.1001/jama.2015.8519